Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.1367 | 0.5 | 0.5 |
Trichomonas vaginalis | hypothetical protein | 0.1367 | 0.5 | 0.5 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.1367 | 0.5 | 0.5 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.1367 | 0.5 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.1367 | 0.5 | 0.5 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.1367 | 0.5 | 0.5 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.1367 | 0.5 | 0.5 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.1367 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 38 % | Antiinflammatory activity of compound expressed as percentage inhibition of carrageenan edema 4 hr after an oral dose of 10 mg/kg. | ChEMBL. | 7205872 |
Inhibition (functional) | = 46 % | Antiinflammatory activity of compound expressed as percentage inhibition of carrageenan edema 4 hr after an oral dose of 33 mg/kg. | ChEMBL. | 7205872 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.